Suppr超能文献

黑色素瘤诊断后发生第二原发性癌症的风险增加。

Increased risk of second primary cancers after a diagnosis of melanoma.

作者信息

Bradford Porcia T, Freedman D Michal, Goldstein Alisa M, Tucker Margaret A

机构信息

Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA.

出版信息

Arch Dermatol. 2010 Mar;146(3):265-72. doi: 10.1001/archdermatol.2010.2.

Abstract

OBJECTIVE

To quantify the risk of subsequent primary cancers among patients with primary cutaneous malignant melanoma.

DESIGN

Population-based registry study.

SETTING

We evaluated data from 9 cancer registries of the Surveillance, Epidemiology, and End Results program from 1973-2006.

PARTICIPANTS

We included 89 515 patients who survived at least 2 months after their initial melanoma diagnosis.

RESULTS

Of the patients with melanoma, 10 857 (12.1%) developed 1 or more subsequent primary cancers. The overall risk of a subsequent primary cancer increased by 28% (observed to expected [O:E] ratio = 1.28). One quarter of the cancers were subsequent primary melanomas (O:E = 8.61). Women with head and neck melanoma and patients younger than 30 had markedly increased risks (O:E = 13.22 and 13.40, respectively) of developing a subsequent melanoma. Second melanomas were more likely to be thin than were the first of multiple primary melanomas (thickness at diagnosis <1.00 mm, 77.9% vs 70.3%, respectively; P < .001). Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively).

CONCLUSIONS

Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers.

摘要

目的

量化原发性皮肤恶性黑色素瘤患者发生后续原发性癌症的风险。

设计

基于人群的登记研究。

背景

我们评估了监测、流行病学和最终结果计划中9个癌症登记处1973 - 2006年的数据。

参与者

我们纳入了89515例在初次黑色素瘤诊断后至少存活2个月的患者。

结果

在黑色素瘤患者中,10857例(12.1%)发生了1种或更多种后续原发性癌症。后续原发性癌症的总体风险增加了28%(观察到的与预期的[O:E]比率 = 1.28)。四分之一的癌症是后续原发性黑色素瘤(O:E = 8.61)。头颈部黑色素瘤女性患者和30岁以下患者发生后续黑色素瘤的风险显著增加(O:E分别为13.22和13.40)。与多个原发性黑色素瘤中的第一个相比,第二个黑色素瘤更可能较薄(诊断时厚度<1.00 mm,分别为77.9%和70.3%;P < 0.001)。黑色素瘤幸存者发生多种癌症的风险增加;风险升高的最常见癌症是乳腺癌、前列腺癌和非霍奇金淋巴瘤(O:E分别为1.10、1.15和1.25)。

结论

与普通人群相比,黑色素瘤幸存者发生后续黑色素瘤的风险增加约9倍。在初次黑色素瘤诊断后20多年,该风险仍然升高。这种风险增加可能归因于行为因素、遗传易感性或医学监测。尽管后续原发性黑色素瘤厚度超过1 mm的百分比低于多个原发性黑色素瘤中的第一个,但仍然相当可观。黑色素瘤幸存者不仅应接受复发监测,还应接受未来原发性黑色素瘤和其他癌症的监测。

相似文献

1
Increased risk of second primary cancers after a diagnosis of melanoma.
Arch Dermatol. 2010 Mar;146(3):265-72. doi: 10.1001/archdermatol.2010.2.
2
Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin.
J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S69-77. doi: 10.1016/j.jaad.2011.04.033.
3
Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
J Am Acad Dermatol. 2010 May;62(5):757-67. doi: 10.1016/j.jaad.2009.07.039. Epub 2010 Mar 12.
4
Risk of Second Primary Cancer in Survivors of In Situ Melanoma.
J Invest Dermatol. 2019 Apr;139(4):842-847. doi: 10.1016/j.jid.2018.11.001. Epub 2018 Nov 10.
6
Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
J Clin Oncol. 2015 Oct 1;33(28):3096-104. doi: 10.1200/JCO.2014.60.2094. Epub 2015 Aug 3.
7
Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
Cancer Med. 2021 Jun;10(11):3575-3583. doi: 10.1002/cam4.3909. Epub 2021 May 7.
8
Italian cancer figures, report 2013: Multiple tumours.
Epidemiol Prev. 2013 Jul-Oct;37(4-5 Suppl 1):1-152.
9
Risk of second malignant neoplasms among long-term survivors of testicular cancer.
J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39. doi: 10.1093/jnci/89.19.1429.

引用本文的文献

2
Lipid-based nanocarriers in combination chemotherapy: a promising strategy for advanced skin cancer management.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 15. doi: 10.1007/s00210-025-04431-1.
3
Do cancer survivors have an increased risk of developing subsequent cancer? A population-based study.
J Transl Med. 2025 Mar 21;23(1):355. doi: 10.1186/s12967-025-06379-5.
4
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases.
Melanoma Res. 2025 Jun 1;35(3):162-169. doi: 10.1097/CMR.0000000000001024. Epub 2025 Feb 6.
6
7
Psychosocial wellbeing in people with melanoma in-situ: a systematic review.
Melanoma Res. 2025 Feb 1;35(1):11-23. doi: 10.1097/CMR.0000000000001007. Epub 2024 Nov 25.
8
Racial and Ethnic Differences in the Risk of Second Primary Melanoma.
JAMA Dermatol. 2024 Dec 1;160(12):1363-1364. doi: 10.1001/jamadermatol.2024.3450.

本文引用的文献

1
Melanoma. Clinical practice guidelines in oncology.
J Natl Compr Canc Netw. 2004 Jan;2(1):46-60. doi: 10.6004/jnccn.2004.0003.
3
Genome-wide association study identifies three loci associated with melanoma risk.
Nat Genet. 2009 Aug;41(8):920-5. doi: 10.1038/ng.411. Epub 2009 Jul 5.
5
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
J Clin Oncol. 2009 Feb 20;27(6):904-10. doi: 10.1200/JCO.2008.17.5398. Epub 2008 Dec 29.
6
Risk of second malignant neoplasms among lymphoma patients with a family history of cancer.
Int J Cancer. 2007 Mar 1;120(5):1099-102. doi: 10.1002/ijc.22414.
7
Recent tanning bed use: a risk factor for melanoma.
Arch Dermatol. 2006 Apr;142(4):485-8. doi: 10.1001/archderm.142.4.485.
8
Multiple primary melanoma: two-year results from a population-based study.
Arch Dermatol. 2006 Apr;142(4):433-8. doi: 10.1001/archderm.142.4.433.
9
Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations.
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2208-12. doi: 10.1158/1055-9965.EPI-05-0321A.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验